This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 May;30(5):840; author reply 840-2.

doi: 10.1097/IAE.0b013e3181dc72f9.

Retinal vein occlusion and low-dose fibrinolytic therapy

Jay Chhablani, Ajit Babu, Mauricio Caraza

PMID: 20453808
DOI: 10.1097/IAE.0b013e3181dc72f9

Comment

Retinal vein occlusion and low-dose fibrinolytic therapy

Jay Chhablani et al. Retina. 2010 May.

. 2010 May;30(5):840; author reply 840-2.

doi: 10.1097/IAE.0b013e3181dc72f9.

Authors

Jay Chhablani, Ajit Babu, Mauricio Caraza

PMID: 20453808
DOI: 10.1097/IAE.0b013e3181dc72f9

No abstract available

PubMed Disclaimer

Comment on

Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion.
Hattenbach LO, Friedrich Arndt C, Lerche R, Scharrer I, Baatz H, Margaron F, Richard G, Behrens-Baumann W, Ohrloff C. Hattenbach LO, et al. Retina. 2009 Jul-Aug;29(7):932-40. doi: 10.1097/IAE.0b013e3181a3b870. Retina. 2009. PMID: 19584651 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer